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Abstract 
BACKGROUND: Breast carcinoma ranks the first among malignant tumours in females and is the chief cause of 
cancer-related mortality. Androgen in implicated in the induction of proliferation and growth of mammary cells 
through binding to their corresponding receptors. Androgens influence the risk of acquiring breast cancer through 
either direct binding to androgen receptors (AR) or indirectly through their transformation to estradiol or competing 
for steroid binding proteins. 
AIM: To study the expression of AR in various breast cancer subtypes and to elucidate its clinical significance by 
correlating it with clinicopathological parameters. 
METHODS: One hundred and fifty breast cancer cases were studied using AR immunohistochemistry, and its 
expression was correlated with different clinicopathologic parameters and with ER, PR, Her-2/neu and Ki 67 
expression. 
RESULTS: AR was expressed in 91 breast carcinoma cases out of 150 examined. There was a statistically 
significant correlation between AR expression and tumour size, mitotic count, tumour necrosis, infiltrative borders, 
the hormonal status of the tumour and subsequently luminal subtypes (p < 0.05). A subset of studied TNBC 
(34.6%) also expressed AR. On the other hand, there was no significant correlation between AR expression and 
other clinicopathological parameters. 
CONCLUSION: Positive AR immunostaining was associated with favourable prognostic factors and luminal 
subtypes (A&B). Also, a subset of TNBC cases showed positive AR expression. These results introduce the 
current potent, next-generation AR- antagonist as possible target therapy in breast cancer. Further researches on 
AR expression in breast cancer are recommended on a larger scale with follow up and survival to validate the 
current results. 
 
 
 
 
 
 
Introduction 
 
Breast carcinoma occupies the first rank 
among malignant tumours in females [1]. It is the 
second most common cause of cancer-related death 
in women, exceeding 1.7 million reported cases per 
year all over the world. Relative difference in 
incidence is noted between various regions as high 
occurrence was recorded in North America and the 
North of Europe, followed by the South region of 
Europe and Latin America, and lowest records were 
reported in Asia and Africa, but with a high tendency 
for rising incidence lately due to increased affluence of 
some of these regions [2]. 
In Egypt, breast cancer ranks second among 
different malignancies [1]. In 2013, breast cancer 
cases were estimated as 18192 [3] and raised to 
23081 in 2018 [1]. 
Breast cancer is a nonuniform disease with 
diverse clinical backgrounds, histomorphology, 
outcome and response to treatment regimens. 
Moreover, neoplasms sharing similar histopathologic 
features can differ in their responses to therapy and 
finally, have different prognosis. This can be attributed 
to molecular diversity among histologically similar 
tumours [4]. 
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Steroid hormones induce the growth of 
mammary cells by attaching to their corresponding 
receptors, resulting in the clonal proliferation of both 
non-neoplastic and neoplastic cells. These signals 
can act directly by affecting hormone receptor-positive 
cells, or through the induction of growth factors 
elaboration that acts indirectly on receptor-negative 
cells. Three major receptors belong to this steroid 
superfamily; estrogen receptor is (ER), progesterone 
receptor (PR) and androgen receptor (AR) [5]. 
The fundamental role of estrogen and 
progesterone receptors in breast cancer prognosis 
and therapy management is well known and 
established. In contrast, few data is known about the 
exact role of the androgen receptor (AR) in breast 
tumorigenesis. The androgen receptor (AR) is more 
widely expressed in breast cancers than other steroid 
receptors [6], [7], [8].  
Androgens influence the risk of acquiring 
breast cancer through either direct binding to AR or 
indirect through their transformation to estradiol or 
competing for steroid binding proteins [9]. 
In the post-menopausal period, women 
develop falling in the estrogen levels, and 
subsequently, adrenal androgens become the 
dominant stock in replenishing estrogen to cells. This 
new metabolic pathway represents the main source of 
estrogens and circulating androgen levels are 
implicated in the rising rates reported for breast 
cancer [10], [ 11]. 
Currently, investigators suggest that AR (+) 
tumours have favourable characteristics and that 
tumours expressing both AR and ER are associated 
with better outcome [12], [13]. 
To date, controversy exists among 
epidemiological, clinical, and preliminary clinical data 
on the basic role of androgens and of ARs in (ER)-
negative breast carcinoma. However, results reported 
from most preliminary clinical researches suggest that 
activated ARs, initiate and induce the proliferation and 
growth, especially in HER2 positive cell lines, due to 
the crosstalk between AR and HER2 pathways. The 
proposed mechanism of action is that androgens are 
bidirectional: mainly proliferative, as androgens are 
the main harbingers of estrogens, but also anti-
proliferative, because stimulated AR limits the ER 
activity [14]. 
In cases of ER-negative disseminated breast 
cancer, AR expression is noted in a subset defined as 
‘molecular apocrine’ tumours and is associated with 
lower 5-year survival [15], [16]. 
The subcategory of TNBC positively 
expressing AR has been termed as the luminal 
androgen receptor (LAR) subtype. The prognostic and 
predictive value of AR in TNBC remains a challenging 
topic of research [17]. 
AR can be a promising candidate for target 
therapy in breast cancer [15]. The AR antagonist 
(enzalutamide) implicated in prostate cancer 
treatment, has shown promising results in some 
patients with advanced TNBC whose tumours were 
AR-positive [18]. 
 
 
Methods 
 
One hundred and fifty cases of breast 
carcinoma with a wide range of age were randomly 
retrieved from the pathology files of the Pathology 
Department, Ahmed Maher Teaching Hospital during 
the period from January 2013 to December 2016. 
Patients with pure in situ duct carcinoma were 
excluded. The study was approved by the local Ethics 
Committee of the General Organization of Teaching 
Hospitals and Institutes. 
The collected specimens were tru-cut needle 
biopsy (n = 10), wide local excision with axillary 
evacuation (n = 85), and modified radical mastectomy 
(n = 55). 
Five µm thick sections were prepared from 
Formalin-fixed paraffin-embedded blocks and stained 
with routine Hematoxylin and eosin for confirmation of 
histopathological diagnosis and further tumour 
subtyping, grading and, staging. Other data were 
assessed such as; foci of tumoral necrosis, 
lymphovascular tumour emboli, perineural invasion, 
lymphocytic response and status of lymph nodes were 
reported. 
The immunohistochemical (IHC) staining 
procedure was done using an immunostainer 
(Shandon Sequenza) through the labelled 
streptavidin-biotin method with the following reagents: 
Citrate buffer, 10X, heat-induced epitope retrieval, 
(Thermo medical Catalog number: AP-9003-500), 
Hydrogen peroxide block (Lab Vision, USA, Catalog 
number: TA-060-HP), Ultravision large volume 
detection system (Lab Vision, USA, Catalog number: 
TP-060-HL) including Ultra V block, Biotinylated goat 
anti-polyvalent plus (link) & Streptavidin peroxidase 
plus (label) and DAB plus substrate system (Lab 
Vision, USA, Catalog number: TA-060-HDX) including 
DAB plus chromogen & DAB plus substrate. The 
primary antibodies were: AR: a mouse polyclonal 
antibody (Thermo Medical Catalog number: MS-433-
R7), ER: a rabbit monoclonal antibody (Thermo 
Medical Catalog number: RM-9101-R7), PR: a rabbit 
monoclonal antibody (Thermo Medical Catalog 
number: RM-9102-R7), HER-2/neu: a mouse 
monoclonal antibody (Thermo Medical Catalog 
number: MS-730-R7) and Ki67: a rabbit polyclonal 
antibody (Thermo Medical Catalog number: RB-9043-
R7). 
The adjacent breast tissue served as a 
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positive internal control for For ER, PR, Her-2/neu and 
Ki 67 while prostatic tissue was used as a positive 
control for AR. The slides were at least examined by 
two pathologists, totally blind to the reported clinical 
data. The following cut-off values were used for 
scoring of IHC-stained slides: 
 - The examined sections were reported as 
ER-positive if more than or equal 1% of ER nuclear 
staining was noted in tumour cells [19]. 
- The examined sections were reported as 
HER-2/neu positive in score 3+; cases with more than 
or equal 10% of tumour cells showed intense 
complete membranous staining [19]. 
- The Ki-67 proliferative activity was 
determined through semi-quantitative scoring. A cut-
off point 20% for the Ki-67 nuclear staining positivity 
was used to classify cases into either low proliferative 
(< 20%) or high proliferative (≥ 20%) [20]. 
- A combination of 4 IHC markers (ER, PR, 
HER-2/neu, and Ki-67) was used for further subtyping 
of breast carcinoma according to St. Gallen 
international expert Consensus, 2013 [21]. 
- The examined sections were reported as 
AR-positive when more than 1% of tumour cells 
showed positive nuclear immunostaining [22], [23]. 
Statistical Package for Social Science (SPSS 
17.0 for Windows; SPSS Inc, Chicago, IL, 2010) was 
used for data analysis. Chi-Square test was used to 
examine the correlation between two qualitative 
variables and between one quantitative and one 
qualitative variable. P-value was set as significant (S) 
when ≤ 0.05. 
 
 
Results 
 
The patient's age showed a wide range of age 
from 31 to 73 years with a mean age of 55.86 ± 13.11 
years. The studied patients were all females. Tumour 
size ranged from 1 cm to 11.5 cm with Mean ± SD 3.2 
± 1.8. Most of the cases were invasive duct carcinoma 
of no special type (NST) with a percentage of 85.3%. 
After exclusion of the Tru-cut cases (10), the 
majority of tumors were histologically grade II (77.1%), 
average mitotic rate (1- 10/10 HPF) (53.5%), were 
negative for tumor necrosis, (89.3%) , had infiltrative 
tumor borders (71.4%), showed moderate lymphocytic 
response (37.1%), had positive lymphovascular 
emboli (88.6%), weres stage T2 (55%) and were N0 
(48.6%). 
Regarding the intrinsic subtypes; after 
exclusion of cases with equivocal Her-2/neu (21), 129 
cases were classified; 40 cases were Luminal A 
(31%), 54 cases were were Luminal B (41.9%), 9 
cases were Her-2 Enriched (7%), and 26 cases were 
triple negative (7%). 
The majority of cases were AR positive 
(60.7%) where AR expression was positive in 39.2% 
of luminal A cases, 43% of luminal B cases, 6.3% of 
Her-2 Enriched and 11.4% of triple-negative cases. 
AR expression was more in the luminal subtypes 
(Figure 1). 
 
Figure 1: A) AR-positive nuclear expression (X200 original magnification) in 
Luminal B breast carcinoma; B) ER-positive nuclear expression (X100 
original magnification); C) negative HER-2 neu membranous 
staining (X100 original magnification); D) high Ki-67 ≥ 20% (X200 
original magnification) 
 
On the correlation of AR expression with the 
clinicopathological parameters; there was a 
statistically significant correlation between AR status 
and both tumour size, and it’s the mitotic count. AR 
expression was associated with tumours of smaller 
size and low mitotic count (P value: 0.017 and < 0.001 
respectively). 
 
Figure 2: A) AR-positive nuclear expression (X200 original 
magnification) in HER-2 enriched breast carcinoma; B) ER-negative 
nuclear expression (X200 original magnification); C) PR negative 
nuclear expression (X200 original magnification); D) positive HER-2 neu 
complete membranous staining (X100 original magnification) 
 
Also, there was a statistically significant 
correlation between AR status and tumour necrosis, 
tumour borders, its hormonal status and subsequently 
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tumour subtype. AR expression was associated with 
the absence of tumour necrosis, with infiltrative 
borders, with positive ER, positive PR and with 
luminal subtypes (P-value: < 0.001, 0.005, 0.004, 
0.016 and 0.006 respectively) (Figures 1, 2, and 3). 
 
Figure 3: A) AR Negative nuclear expression (X200 original magnification) 
in Triple Negative breast carcinoma; B)ER-negative nuclear expression 
(X200 original magnification); C) PR negative nuclear expression (X200 
original magnification); D) negative HER-2 neu membranous staining 
(X200 original magnification) 
 
No correlation could be found between AR 
status and patients age, tumour site, multifocality, 
histologic type, grade, lymphocytic response, 
lymphovascular invasion, perineural invasion, T stage, 
N stage, Her-2/neu status and ki 67 status (Table 1). 
Table 1: Clinicopathological findings and their correlation with 
androgen receptors expression 
 AR - n (%) AR + n (%) Total n (%) P value 
Right side  
Left side 
27 (45.8) 
32 (54.2) 
48 (52.7) 
43 (47.3) 
75 (50) 
75 (50) 
0.33 
Unifocal  
Multifocal 
49 (89.1) 
6 (10.9) 
75 (88.2) 
10 (11.8) 
124 (88.6) 
16 (11.4) 
0.924 
IDC (NST) 55 (93.2) 73 (80.2) 128 (85.3) 
0.125 
ILC 0 (0) 10 (11) 10 (6.7) 
Tubular/Cribriform/ mixed 3 (5.1) 4 (4.4) 7 (4.7) 
 
Others 1 (1.7) 4 (4.4) 5 (3.3) 
Grade I&II 50 (90.9) 84 (98.8) 134 (95.7) 
0.087 
III 5 (9.1) 1 (1.2) 6 (4.3) 
No mitosis 12 (21.4) 34(40.5) 46 (32.9) 
< 0.001* 1-10/10 HPF 28 (50) 47 (56.9) 75 (53.5) 
> 10/10 HPF 15 (28.6) 4 (3.6) 19 (13.6) 
Necrosis abscent 42 (76.4) 83 (97.6) 125 (89.3) 
< 0.001* 
Present 13 (23.6) 2 (2.4) 15 (10.7) 
Infiltrative border 32 (58.2) 68 (80) 100 (71.4) 
0.005* 
Pushing 23 (41.8) 17 (20) 40 (28.6) 
No Lymphocytic response 9 (16.4) 23 (27.1) 32 (22.9) 
0.14 
With lymphocytic response 46(83.6) 62(73.9) 108(77.1) 
No vascular emboli 8 (16.5) 8 (27.1) 16 (11.4) 
0.14 
With vascular emboli 47 (83.5) 77 (72.9) 124 (88.6) 
No perineural invasion 55 (100) 84 (98.8) 139 (99.3) 
0.83 
With perineural invasion 0 (0) 1 (1.2) 1 (0.7) 
T Stage I & II 43 (78.2) 74 (87.1) 117 (83.6) 
0.166 
III&IV 12 (21.8) 11 (12.9) 23 (16.4) 
N Stage N0 25 (45.5) 43 (50.6) 68 (48.6) 
0.55 
N1, N2 30 (55.5) 42 (49.4) 72 (51.4) 
ER-  
ER+ 
22 (37.7) 
37 (62.3) 
15 (16.7) 
76 (83.3) 
37 (24.7) 
113 (75.3) 
0.004* 
PR-  
PR+ 
26 (45.3) 
32 (54.7) 
23 (25) 
69 (75) 
49 (32.7) 
101 (67.3) 
0.016* 
Her2-  
Her2+ 
Equivocal Her2 
38 (67.9) 
9 (15.1) 
12 (17) 
76 (84) 
6 (6.2) 
9 (9.9) 
114 (76) 
15 (10) 
21 (14) 
 
0.084 
Low Ki 67 
High Ki 67 
17 (29.3) 37 (40.2) 54 (36) 
0.139 
42 (70.7) 54 (59.8) 96 (64) 
Luminal A 
Luminal B  
Her-2 enriched Triple 
Negative 
9 (18) 31 (39.2) 40 (31) 
0.006* 
20 (40) 
4 (8) 
17 (34) 
34 (43) 
5 (6.3) 
9 (11.4) 
54 (41.9) 
9 (7) 
26 (20.2) 
 
Discussion 
 
The chief role of androgen receptor signalling 
in neoplastic breast cells remains questionable. It has 
been reported in previous studies to be involved in the 
proliferation and growth of normal mammary cells 
[24]. 
This work studied the relation between AR 
expression and clinicopathological parameters in 150 
cases of invasive breast carcinoma. 
A significant correlation was found between 
AR expression and tumour size. This finding is in 
agreement with Ogawa et al., [25], Niemeier et al., 
[26], Collins et al., [27], and Aleskandarany et al., [28] 
studies which found that AR expression was higher in 
the smaller tumours. On the other hand, Gonzalez et 
al.29 and Samaka et al., [30] found no significant 
correlation between AR expression and the size of the 
tumour. Gonzalez et al., [29] used both tissue 
microarrays and immunohistochemistry and Samaka 
et al., [30] used a smaller number of cases. 
AR expression is significantly associated with 
infiltrative borders of the tumour, and this is in 
concordance with Putti et al., [31]. But this is in 
contrast to Gonzalez et al., [29] study which found no 
significant relation between AR expression and the 
type of tumour borders. This discrepancy might be the 
result of their use of tissue microarray in testing for 
AR. 
The mitotic count is significantly inversely 
correlated to AR expression where the cases with 
lower mitotic figures showed a higher percentage of 
AR expression. This is in harmony with Safarpour et 
al., [32] and Aleskandarany et al., [28]. 
AR expression was significantly associated 
with the absence of tumour necrosis, and this is was 
similar to Niemeier et al., [26] study results. 
A significant correlation between AR 
expression and hormonal status was found. This is by 
Park et al., [6], Qi et al., [33], Safarpour et al., [32], 
Vera-Badillo et al., [34], and Chottanapund et al., [35]. 
On the contrary; Gonzalez et al.
29
 found no correlation 
between AR status and the hormonal status of breast 
cancer. This might be the result of their use of tissue 
microarray in testing for AR. 
As Ogawa et al., [25], Park et al., [6] and Qi et 
al., [33], no significant relation between AR expression 
and Her-2/neu expression could be found, though 
Agrawal et al., [36], Chottanapund et al., [35], and 
Samaka et al., [30] found that AR expression is more 
in tumours expressing Her-2/neu. This might be due 
to different primary antibodies used. 
No significant relation between AR expression 
and Ki 67 expression was found as Vera- Badillo et 
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al., [34], but in contrast to Qi et al., [33], and Samaka 
et al., [30], this might be due to their use of 14 % as 
cut-off, not 20% as we used. 
Regarding the correlation between AR 
expression and the subtypes, AR was expressed in 
significantly higher proportions of luminal breast 
carcinoma cases. This is by Collins et al., [27], Qi et 
al., [33], Aleskandarany et al., [28] and Samaka et al., 
[30]. 
In our study, the triple negative cases were 
20.2%. This is within the documented range for triple 
negative cases (15-20%) of Kohler et al., a study [37]. 
AR was expressed in 34.6% of the TN cases, and that 
is within the wide range of 6.6 to 75% documented by 
Rampurwala et al., [38]. These subsets of patients are 
possible candidates for the promising anti-androgen 
target therapy. 
No correlation could be found between AR 
status and patients age, tumour site, multifocality, 
histologic type, grade, lymphocytic response, 
lymphovascular invasion, perineural invasion, T stage, 
N stage, Her-2/neu status and ki 67 status. 
Gonzalez et al., [29] also found no significant 
correlation between AR expression and histologic 
grade, lymphocytic response, lymphovascular 
invasion or N stage. 
Ogawa et al., [25] and Collins et al., [27] 
found androgen receptor-positive tumours were lower 
grade and more often node-negative. 
Soiland et al., [39] found no significant 
correlation between AR expression and patients age. 
Park et al., [6] revealed a significant 
correlation between AR expression and both 
histologic type and grade. 
Qi et al., [33] did not find a significant 
correlation between AR expression and both patients 
age and N stage. 
Ruibal et al., [40] tested AR expression in 816 
breast cancers using immunohistochemistry and 
found no relation between AR expression and the 
tumour multifocality. 
Agrawal et al., [36] found no significant 
correlation between AR expression and both 
histologic type and N stage but found a significant 
correlation between AR expression and histologic 
grade. 
Aleskandarany et al., [28] found that nuclear 
AR immunostaining was significantly associated with 
features favouring good prognosis including older age 
groups, smaller tumour size, lower histologic grade 
and lobular carcinoma. 
Samaka et al., [30] found a significant relation 
between AR expression and the patient's age and no 
significant relation with histologic type, 
lymphovascular invasion or N stage. 
In the highlight of the previously mentioned 
results, we conclude that positive AR immunostaining 
was associated with smaller tumour size, infiltrative 
margins, lower mitotic count, negative tumour 
necrosis, positive ER and PR expression and mainly 
luminal subtypes (A&B) and in a subset of TNBC 
cases. 
The most used therapy for advanced BC 
(Tamoxifen-resistant-BCs and TNBCs) is based on 
the use of AR antagonists, such as bicalutamide and 
enzalutamide, a first- and second-generation AR 
antagonist, respectively [41], [42]. Both the 
antagonists have been used in clinical trials with 
positive results [43]. Other therapies for TNBC are 
based on the use of CYP17A1 inhibitors, such as 
abiraterone acetate and seviteronel. These inhibitors 
reduce the androgen production and 11the androgen 
levels. They are now being tested in phase 2 clinical 
trials [44], [45], alone or in combination with AR 
antagonists [46]. 
In conclusion, positive AR expression was 
associated with favourable prognostic factors and 
luminal subtypes (A&B). Also, a subset of TNBC 
cases showed positive AR expression. These results 
introduce the current potent, next-generation AR- 
antagonist as possible target therapy in breast cancer. 
Further researches on AR expression in breast cancer 
are recommended on a larger scale with follow up and 
survival to validate the current results. 
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